Obs Eva Sa OBSV
We take great care to ensure that the data presented and summarized in this overview for ObsEva SA is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in OBSV
Top Purchases
Top Sells
About OBSV
ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. The company is also involved in developing Ebopiprant, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, which is in Phase II clinical trial as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist that is in Phase I clinical trial to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. ObsEva SA was founded in 2012 and is headquartered in Geneva, Switzerland.
Insider Transactions at OBSV
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 06
2023
|
Ernest Loumaye Director |
BUY
Open market or private purchase
|
Direct |
4,000,000
+28.57%
|
$0
$0.1 P/Share
|
|
Feb 28
2023
|
Ernest Loumaye Director |
BUY
Open market or private purchase
|
Direct |
4,000,000
+40.0%
|
$0
$0.11 P/Share
|